Summary

Original source:
http://www.fool.com/News/mft/2005/mft05030911.htm

Details

• Everyone knows that it's the pharmaceutical industry's job to come up with new products to cure what ails us.
• From Pfizer's (NYSE: PFE) Lipitor to Eli Lilly's (NYSE: LLY) Cialis, drugmakers have done a remarkable job of zeroing in on problems and finding treatments for them.
• It's not too often, though, that pharmaceutical outfits develop medicine that addresses multiple conditions at once.
• The company intends to ask the Food and Drug Administration for approval to sell the drug rimonabant, which it plans to call Acomplia, within the next few months, the Associated Press reports.
• Sanofi-Aventis says that the drug allowed patients who took it for more than two years in trials to lose an average of 16 pounds.
• What's more, most of the weight patients lost in the first year, they kept off.
• Wyeth (NYSE: WYE), for instance, is still working to pay off the liability associated with the cardiovascular side effects of its fen-phen diet medication.
• The medicine, known as a cannabinoid type 1 receptor antagonist, acts by blocking the sensation of pleasure one receives from the brain when eating.
• This unique mechanism of action may mean that the drug has applications in a variety of other areas, including those associated with addiction.
• Sanofi already has evidence that Acomplia may be useful in treating nicotine addiction, and researchers are also interested in the medicine for potential use in alcoholism and other drug dependencies.
• In other words, Acomplia may be a regular "vice-be-gone."
• Of course, given the recent eruption of problems with drugs already on the market, a new, more cautious FDA may take its time approving Acomplia.
• Still, with its potentially broad spectrum of use, Acomplia may worth the wait.

Related Articles

Popular Topics: Weight loss, Addictions, Smoking, Diabetes, Breast cancer, Prostate cancer, Heart disease, Depression, High cholesterol, Osteoporosis, Vaccines, Autism, ADHD, Infertility, Weight loss, Cancer, Alzheimer's, Trans fats, Acrylamides, Fluoride, Mercury	Take Action: Support NaturalNews.com Email this article to a friend Share this article on: NewsVine | digg | del.icio.us Permalink to this article: http://www.NaturalNews.com/005832_weight_loss_addictions_smoking.html Reprinting this article: Non-commercial use OK, cite NaturalNews.com with clickable link. <a href = "http://www.NaturalNews.com/005832_weight_loss_addictions_smoking.html">Proposed weight loss pill may help with smoking, other addictions, too</a>
Receive our Natural Health Newsletter for FREE Subscribe now (it's free!) to win. We randomly choose a subscriber each month to send $100 in eco-home products or a RealGoods.com gift certificate (our choice). Plus, you'll receive FREE news, articles and action alerts from NaturalNews.com editors and join over 800,000 monthly readers who report extraordinary health improvements after becoming a subscriber! Receive breaking news alerts on natural health solutions, renewable energy, the environment, global warming and more. Receive a free instant download of our $29 Secret Sources guide that reveals top sources for little-known health and diet solutions.	Your Email Address: Free Subscription Code: Enter the numbers you see: 100% free of charge. Unsubscribe anytime. Absolutely no spam. We respect your email privacy.
Recommended Special Report: Seven Words that can Change the World by Joseph R. Simonetta Read this special report now... "Seven Words That Can Change the World reveals the astonishing, simple truths that have the power to forever transform our world for the better while freeing our minds from the enslavement of limiting beliefs. This is not a text for the simple-minded; it is a guiding philosophy for the mindful, intelligent few who are wise enough to seek out -- and recognize -- the higher simplicities of truly purposeful living." - Mike Adams, the Health Ranger, editor of NaturalNews.com	More on NaturalNews.com: • Streaming Health Ranger Videos • CounterThink Cartoons • FREE Special Reports • Podcasts